Warfarin proves resilient against oral blood thinners

Date August 21, 2012

The bullish picture of the anticoagulant market of two years ago has been pared back as the three newest products in the space have each experienced difficulties: Eliquis’s delay in stroke prevention, safety worries over serious bleeding with Pradaxa, and Xarelto’s struggles to show efficacy over incumbent warfarin.

Now come early registry data from the American College of Cardiology indicating no mad rush to the new oral products in spite of warfarin’s complicated dosing and its own bleeding risk. Familiarity, price and an unwillingness to switch stable patients are likely factors holding the novel blood-thinners at bay – data from EvaluatePharma show that consensus sales forecasts for all three products have already come down in recent months (see table).

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd